Compare SYSCO Corporation (SYY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs Twist Bioscience Corp — how do they compare? SYSCO Corporation trades at $84.5 (market cap $40.32B), while Twist Bioscience Corp trades at $124.64 (market cap $7.72B). The key difference: SYSCO Corporation is far larger — about 5.2× Twist Bioscience Corp's market cap, and SYSCO Corporation pays a 2.61% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SYY | TWST | |
|---|---|---|
Market Cap | $40.32B | $7.72B |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $124.88 |
52-Week Low | $69.30 | $24.16 |
Enterprise Value | $53.50B | $7.65B |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sysco (SYY) trades at $84.73, up 1.03% today, with a bullish technical signal from moving averages and a consensus analyst price target of $88.25. The company reported strong Q4 2026 earnings, beating EPS estimates with $1.53 versus $1.51 expected, driven by U.S. foodservice volume growth and cost efficiencies. Revenue reached $81.37 billion in 2025, with net income of $1.83 billion, though profit margins remain thin at 2.08%. Recent news highlights CEO discussions on CNBC and operational initiatives, including AI-driven efficiencies.
The outlook for SYY is positive, supported by earnings beats, steady cash flow, and analyst optimism, but risks include competitive pressures, supply chain disruptions, and macroeconomic uncertainty. Upside potential exists if the company maintains volume growth and margin improvements, but investors should monitor debt levels and food safety issues highlighted in recent reports.
Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.
Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
